纵横研报
Ticker Detail

HIK.LSE

14.88-0.53% Hikma Pharmaceuticals PLC Drug Manufacturers - Specialty & Generic
00Reports UK 医疗健康
医疗健康 · 专科与仿制药

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

MARKET 市值 3.33B GBP PE 11.6x Fwd 10.9x 52W £11.54 – £19.65 EODHD · Q 2025-12-31 · 同步 2026-07-14
QUALITY PEG 2.38 营收 YoY 8.5% ROE 16.5% 营业利润率 16.2% 净利润率 12.0%
ANALYST 股息率 5.20%

暂无相关研报

数据库中已收录该标的的基本面数据,可发起一份定制研报。

CUSTOM RESEARCH · 定制研报 没找到完全契合的标的?让我们替你做一份。 告诉我们你关心的标的与偏好,1 个工作日内在站内上线。 开始定制